Mesoblast (MESO) Projected to Post Quarterly Earnings on Thursday

Mesoblast (NASDAQ:MESO) is expected to be posting its results before the market opens on Thursday, February 26th. Analysts expect Mesoblast to post earnings of ($0.2370) per share and revenue of $30.6790 million for the quarter.

Mesoblast Trading Down 0.2%

Shares of Mesoblast stock opened at $16.88 on Friday. Mesoblast has a 1 year low of $9.61 and a 1 year high of $21.50. The company’s fifty day simple moving average is $18.06 and its 200-day simple moving average is $16.84. The company has a market cap of $2.18 billion, a price-to-earnings ratio of -19.18 and a beta of 2.15. The company has a current ratio of 1.99, a quick ratio of 1.77 and a debt-to-equity ratio of 0.11.

Institutional Investors Weigh In On Mesoblast

Several large investors have recently modified their holdings of MESO. Quadrature Capital Ltd bought a new position in shares of Mesoblast during the 4th quarter worth approximately $479,000. AQR Capital Management LLC grew its position in Mesoblast by 80.5% in the fourth quarter. AQR Capital Management LLC now owns 25,215 shares of the company’s stock valued at $455,000 after acquiring an additional 11,242 shares during the period. &PARTNERS acquired a new position in Mesoblast during the fourth quarter worth $334,000. Opal Capital LLC bought a new position in shares of Mesoblast during the fourth quarter valued at $307,000. Finally, Marshall Wace LLP bought a new position in shares of Mesoblast during the fourth quarter valued at $286,000. 1.43% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mesoblast in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.